PYC Therapeutics Limited (PYC.AX)
AUD 1.03
(-2.37%)
AUD 1.03
(-2.37%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 10.18 Million AUD | 16.75% |
| 2023 | 8.72 Million AUD | 69.4% |
| 2022 | 5.14 Million AUD | 28.2% |
| 2021 | 4.01 Million AUD | 197.35% |
| 2020 | 1.35 Million AUD | 236.12% |
| 2019 | 401.87 Thousand AUD | -77.32% |
| 2018 | 1.77 Million AUD | 18.97% |
| 2017 | 1.48 Million AUD | 3.74% |
| 2016 | 1.43 Million AUD | 74.26% |
| 2015 | 823.8 Thousand AUD | 2.28% |
| 2014 | 805.47 Thousand AUD | -24.55% |
| 2013 | 1.06 Million AUD | 33.25% |
| 2012 | 801.16 Thousand AUD | -38.77% |
| 2011 | 1.3 Million AUD | -34.81% |
| 2010 | 2 Million AUD | 27.36% |
| 2009 | 1.57 Million AUD | 91.17% |
| 2008 | 824.36 Thousand AUD | -38.36% |
| 2007 | 1.33 Million AUD | 86.28% |
| 2006 | 717.9 Thousand AUD | 136.46% |
| 2005 | 303.61 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 9.07 Million AUD | 0.0% |
| 2024 Q4 | 10.18 Million AUD | 0.0% |
| 2024 FY | 10.18 Million AUD | 16.75% |
| 2023 FY | 8.72 Million AUD | 69.4% |
| 2023 Q4 | 8.72 Million AUD | 0.0% |
| 2023 Q2 | 8.59 Million AUD | 0.0% |
| 2022 Q2 | 4.21 Million AUD | 0.0% |
| 2022 Q4 | 5.14 Million AUD | 0.0% |
| 2022 FY | 5.14 Million AUD | 28.2% |
| 2021 Q4 | 4.01 Million AUD | 0.0% |
| 2021 Q2 | 1.76 Million AUD | 0.0% |
| 2021 FY | 4.01 Million AUD | 197.35% |
| 2020 Q2 | 1.51 Million AUD | 0.0% |
| 2020 FY | 1.35 Million AUD | 236.12% |
| 2020 Q4 | 1.35 Million AUD | 0.0% |
| 2019 Q4 | 401.87 Thousand AUD | 0.0% |
| 2019 Q2 | 1.63 Million AUD | 0.0% |
| 2019 FY | 401.87 Thousand AUD | -77.32% |
| 2018 Q4 | 1.77 Million AUD | 0.0% |
| 2018 FY | 1.77 Million AUD | 18.97% |
| 2018 Q2 | 1.79 Million AUD | 0.0% |
| 2017 Q4 | 1.48 Million AUD | 0.0% |
| 2017 Q2 | 1.05 Million AUD | 0.0% |
| 2017 FY | 1.48 Million AUD | 3.74% |
| 2016 FY | 1.43 Million AUD | 74.26% |
| 2016 Q4 | 1.43 Million AUD | 0.0% |
| 2016 Q2 | 891.99 Thousand AUD | 0.0% |
| 2015 FY | 823.8 Thousand AUD | 2.28% |
| 2015 Q4 | 823.8 Thousand AUD | 0.0% |
| 2015 Q2 | 881.45 Thousand AUD | 0.0% |
| 2014 FY | 805.47 Thousand AUD | -24.55% |
| 2014 Q4 | 805.47 Thousand AUD | 0.0% |
| 2014 Q2 | 835.71 Thousand AUD | 0.0% |
| 2013 Q1 | 803.77 Thousand AUD | 0.33% |
| 2013 FY | 1.06 Million AUD | 33.25% |
| 2013 Q4 | 1.06 Million AUD | 1.76% |
| 2013 Q3 | 1.04 Million AUD | 30.52% |
| 2013 Q2 | 803.77 Thousand AUD | 0.0% |
| 2012 FY | 801.16 Thousand AUD | -38.77% |
| 2012 Q4 | 801.16 Thousand AUD | 0.0% |
| 2011 FY | 1.3 Million AUD | -34.81% |
| 2011 Q4 | 1.3 Million AUD | 0.0% |
| 2010 Q4 | 2 Million AUD | 0.0% |
| 2010 FY | 2 Million AUD | 27.36% |
| 2009 FY | 1.57 Million AUD | 91.17% |
| 2009 Q4 | 1.57 Million AUD | 0.0% |
| 2008 Q4 | 824.36 Thousand AUD | 0.0% |
| 2008 FY | 824.36 Thousand AUD | -38.36% |
| 2007 Q4 | 1.33 Million AUD | 0.0% |
| 2007 FY | 1.33 Million AUD | 86.28% |
| 2006 FY | 717.9 Thousand AUD | 136.46% |
| 2006 Q4 | 717.9 Thousand AUD | 0.0% |
| 2005 FY | 303.61 Thousand AUD | 0.0% |
| 2005 Q4 | 303.61 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AdAlta Limited | 3.54 Million AUD | -187.479% |
| Acrux Limited | 5.68 Million AUD | -79.077% |
| Actinogen Medical Limited | 1.61 Million AUD | -530.45% |
| AnteoTech Limited | 4.07 Million AUD | -149.901% |
| Argenica Therapeutics Limited | 2.42 Million AUD | -319.665% |
| Arovella Therapeutics Limited | 2.05 Million AUD | -395.182% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -3218.926% |
| Alterity Therapeutics Limited | 5.42 Million AUD | -87.701% |
| Amplia Therapeutics Limited | 3.42 Million AUD | -197.19% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -981.642% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -2664.066% |
| Biome Australia Limited | 5.37 Million AUD | -89.533% |
| Biotron Limited | 737.5 Thousand AUD | -1280.879% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | -172.88% |
| BTC Health Limited | 203.94 Thousand AUD | -4893.474% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 20.456% |
| CSL Limited | 27.88 Billion AUD | 99.963% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | -22.232% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 63.773% |
| Cynata Therapeutics Limited | 1.17 Million AUD | -769.651% |
| Dimerix Limited | 13.89 Million AUD | 26.696% |
| EZZ Life Science Holdings Limited | 4.22 Million AUD | -140.807% |
| Hexima Limited | 248.67 Thousand AUD | -3995.424% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -873.972% |
| Immuron Limited | 2.84 Million AUD | -258.528% |
| Immutep Limited | 10.97 Million AUD | 7.245% |
| Imugene Limited | 33.14 Million AUD | 69.273% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -2259.449% |
| Memphasys Limited | 5.59 Million AUD | -82.106% |
| Nanollose Limited | 465.64 Thousand AUD | -2087.103% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 76.185% |
| Noxopharm Limited | 1.28 Million AUD | -690.313% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -11785.777% |
| Nyrada Inc. | 855.63 Thousand AUD | -1090.24% |
| Orthocell Limited | 22.08 Million AUD | 53.882% |
| PharmAust Limited | 896.6 Thousand AUD | -1035.848% |
| Patrys Limited | 691.36 Thousand AUD | -1373.041% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | -184.127% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | -526.357% |
| Prescient Therapeutics Limited | 2.32 Million AUD | -337.919% |
| Race Oncology Limited | 1.91 Million AUD | -431.411% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 77.208% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 35.922% |
| Starpharma Holdings Limited | 8.69 Million AUD | -17.085% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 95.916% |
| Tissue Repair Ltd | 1.35 Million AUD | -653.872% |
| Zelira Therapeutics Limited | 9.35 Million AUD | -8.844% |